erythra-derm (Erythromycin) solution
[Paddock Laboratories, Inc.]
Erythromycin is an antibiotic produced from a strain of Streptomyces erythraeus. It is basic and readily forms salts with acids.
Chemically, erythromycin is (3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*, 13S*, 14R*)-4-[(2,6-Dideoxy-3-C-methyl-3-0-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2, 10-dione with a molecular formula of C37H67NO13 and a molecular weight of 733.94. The structural formula is as follows:
Erythromycin Topical Solution USP 2% contains 20 mg/mL of erythromycin base in a vehicle consisting of alcohol (66%), propylene glycol, and citric acid to adjust pH.
Although the mechanism by which Erythromycin Topical Solution acts in reducing inflammatory lesions of acne vulgaris is unknown, it is presumably due to its antibiotic action.
Erythromycin Topical Solution is indicated for the topical control of acne vulgaris.
Erythromycin Topical Solution is contraindicated in persons who have shown hypersensitivity to erythromycin or any of the other listed ingredients.
The safe use of Erythromycin Topical Solution during pregnancy or lactation has not been established.
The use of antibiotic agents may be associated with the overgrowth of antibiotic-resistant organisms. If this occurs, administration of this drug should be discontinued and appropriate measures taken.
Erythromycin Topical Solution is for external use only and should be kept away from the eyes, nose, mouth and other mucous membranes. Concomitant topical acne therapy should be used with caution because a cumulative irritant effect may occur, especially with the use of peeling, desquamating or abrasive agents.
Long term animal studies to evaluate carcinogenic potential, mutagenicity, or the effect on fertility of erythromycin have not been conducted.
Pregnancy Category C. Animal reproduction studies have not been conducted with erythromycin. It is also not known whether erythromycin can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Erythromycin should be given to a pregnant woman only if clearly needed.
Erythromycin is excreted in breast milk. Caution must be exercised when erythromycin is administered to a nursing woman.
Adverse conditions reported with the use of erythromycin topical solutions include dryness, tenderness, pruritis, desquamation, erythema, oiliness, and burning sensation. Irritation of the eyes has also been reported. A case of generalized urticarial reaction, possibly related to the drug, which required the use of systemic steroid therapy has been reported.
Erythromycin Topical Solution should be applied to the affected areas twice a day after the skin has been thoroughly washed with warm water and soap and patted dry. Apply contents after installing applicator (below) by tilting bottle and rubbing applicator lightly over affected areas until skin is thoroughly wetted. Close tightly after each use. Acne lesions on the face, neck, shoulder, chest, and back may be treated in this manner.
60 mL Bottle: NDC 0574-0014-02
Keep tightly closed. Store at controlled room temperature, 15° - 30°C (59° - 86°F).
Paddock Laboratories, Inc.
Minneapolis, Minnesota 55427
Data are from FDA and U.S. National Library of Medicine.